Avatar

Contemporary Design of MM Treatment : Complexity of Myeloma Biology, Addressing Resistance, Maximize Response Depth

By Gareth J Morgan 2 Videos
362 views
August 3, 2018
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
03:17
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Highlights From the International Myeloma S…

Feat. J. Richter
23:34
MyCancerHaven

Experts Discuss the Diagnosis and Management of High-Risk Multiple M…

Feat. R. Vij, M. Alsina
42:37
University of Colorado Department of Medicine

Multiple Myeloma in 2023: An Oncological Success Story

Feat. P. Forsberg
04:34
Icahn School of Medicine at Mount Sinai

Revisiting the Role of Alkylating Agents in Myeloma: Up-to-Date Evid…

Feat. J. Richter
10:32
Penn Medicine Abramson Cancer Center

Penn Medicine Updates From Recent Meetings in Hematologic Malignanci…

Feat. A. Garfall
26:08
GRACE

2023 Updates on Advances in Multiple Myeloma

Feat. S. Kumar
10:25
5th SOHO Italy Annual Conference

SOHO Italy 2023: Is It Time for a Biomarkers-Driven Approach in Smol…

Feat. I. Ghobrial
47:07
Louisville Hematology Highlights

Updates on the Progress in Multiple Myeloma

Feat. D. Reece
15:28
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Next Generation Therapeutics (Degraders & Targeted Th…

Feat. A. Nooka
26:10
MyCancerHaven

Multiple Myeloma 101: Epidemiology, Diagnosis and Staging

Feat. R. Vij, S. Kumar
11:31
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Epigenetic Drivers of Disease Progression i…

Feat. F. Prosper
43:50
MyCancerHaven

The Basics of Diagnostic Testing in Multiple Myeloma: How to Interpr…

Feat. R. Vij, C. Emmitt Cole
09:52
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Epigenetic Regulation of CD38/48 by KDM6A a…

Feat. J. Liu
11:42
Ola Landgren

A New System for Genomic Classification and Individualized Prognosis…

16:29
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Review of MRD in MM: Why, When, Where, and How?

Feat. N. S. Raje
30:24
University of Colorado Cancer Center

MRD in MM: How We Measure Disease Generally and What It Means for th…

Feat. B. Harry
14:10
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

How I Manage Infections in Myeloma to Decrease Morbidity/Mortality

Feat. A. Chari
05:53
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Post-Induction Undetectable Flow MRD Amelio…

Feat. G. Seval
22:16
SOHO Italy 1st School of Multiple Myeloma

Molecular Pathogenesis of MM: MGUS and SMM, Genomic Complexity of th…

Feat. N. Bolli
23:07
Extracellular Vesicles and Their Role in Patients With Multiple Myeloma

How to Incorporate Liquid Biopsies Into Characterising MM: An Evolvi…

Feat. A. Spencer